Ep. 184 - Healthcare Costs, Pharma Policy & HSAs: A Market-Based Approach w/Isabelle Marchese

Why does healthcare keep getting more expensive — and are policymakers making the problem worse?

On this episode of the Federal Newswire Lunch Hour Podcast, host Andrew Langer sits down with Isabelle Marchese, Director of Health Policy at Americans for Tax Reform, to break down the real drivers behind rising healthcare costs and the policy decisions shaping the system.

Marchese explains how government intervention has distorted basic supply-and-demand dynamics in healthcare — increasing demand without expanding supply — and why that imbalance continues to push costs higher for patients.

A major focus of the conversation is the growing push for pharmaceutical price controls, including policies like “most favored nation” pricing and provisions in the Inflation Reduction Act. Marchese outlines the unintended consequences of these approaches, particularly their impact on innovation and long-term drug development.

The discussion also covers:
• Why healthcare should be viewed as a resource economics problem
• How supply and demand imbalances drive rising costs
• The real impact of pharmaceutical price controls on innovation
• Why fewer new drugs could result from current policies
• The long-term value of innovation and generic drug development
• How intellectual property protections shape medical breakthroughs
• The economic realities of drug development (cost, time, and risk)
• Why Health Savings Accounts (HSAs) reduce costs for consumers
• How HSAs reconnect patients to healthcare spending decisions
• Recent policy changes expanding HSAs — and what’s still needed
• The role of tariffs in pharmaceutical policy and supply chains
• The risks of overregulation and government “tinkering”
• Why ideological consistency matters in healthcare policy debates

The conversation also explores a broader theme: how political incentives and short-term thinking often lead to policies that feel popular in the moment but create long-term challenges for innovation, affordability, and access.

At its core, the episode makes the case that sustainable healthcare reform requires aligning incentives, expanding supply, and allowing market forces to work — rather than relying on heavy-handed policy interventions.

00:00 — Intro + Isabelle Marchese joins
00:35 — Early interest in politics and healthcare
02:18 — Healthcare as a supply and demand problem
03:28 — Why costs rise when supply doesn’t increase
04:23 — Americans for Tax Reform’s healthcare focus
05:02 — Pharmaceutical policy and price control debates
06:17 — Inflation Reduction Act and drug pricing impacts
07:19 — How price controls affect innovation
08:29 — Why fewer drugs could be developed
09:18 — Generic drugs and long-term cost reductions
10:59 — Economics of drug development explained
12:24 — Why investment depends on recouping costs
13:33 — Ideological consistency in policy debates
15:00 — Political incentives and policy contradictions
17:15 — Health Savings Accounts (HSAs) explained
18:26 — How HSAs lower healthcare costs
19:14 — Vision for expanding HSAs
20:22 — Healthcare vs insurance: key differences
21:57 — Market forces and consumer behavior
22:22 — Recent HSA policy changes
23:22 — Why reform efforts stall
25:21 — Tariffs and pharmaceutical supply chains
26:19 — National security vs economic tradeoffs
27:33 — Free rider problem and global pricing
29:45 — Final thoughts on healthcare reform
31:00 — Outside interests: cooking and food prep
34:59 — Closing

Watch Full-Length Episodes: https://www.youtube.com/@Lunchhour_FNW